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1. As the current EU Drugs Strategy expires at the end of the year, the Presidency decided to 
propose Council conclusions on the new strategy, aiming to draw guidelines for the new EU 
drugs strategy. 
 
2. Draft Council conclusions were presented and examined during the HDG meetings of 18 
April and 22 May 2012.  
 
3. On the basis of these discussions and taking into account the comments provided after these 
discussions, the draft Council Conclusions on new drugs strategy were finalised. 
 
4. Consequently, COREPER is invited to confirm the agreement on the text of the draft 
Conclusions as set out in annex and to submit it to the Council for approval. 
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AEX 
Draft Council Conclusions on the new EU drugs strategy 
 
THE COUCIL OF THE EUROPEA UIO, 
 
RECALLIG 
 
- the EU Drugs Strategy 2005-2012
1
, which has formed the basis of the EU drug policy since 
2005 and provided the framework for two consecutive four-year Action Plans; 
- the EU Drug Action Plan 2005-2008
2
 and the EU Drug Action Plan 2009-2012
3
 and the final 
report of the evaluation of the EU Drug Action Plan 2005-2008
4
; 
- the conclusions and recommendations of the Report on the independent assessment of the EU 
Drugs Strategy 2005-2012 and its action plans; 
- the EMCDDA trend report prepared for the evaluation of the 2005-2012 EU Drugs Strategy, 
which indicated changes in the EU drug situation over the last eight years; 
- the Stockholm programme which names the following principles on which the new EU drugs 
strategy should be based: improving coordination and cooperation by using all available 
means under the Lisbon Treaty, mobilising the civil society and contributing to research and 
comparability of information
5
; 
- the European Pact to combat international drug trafficking – disrupting cocaine and heroin 
routes
6
 and the European Pact against synthetic drugs
7
 which seek to improve coordination 
between the various initiatives launched to clamp down on drug trafficking; 
- the EU policy cycle for organised and serious international crime
8
 – an instrument developed 
to identify priority threats to the EU and coordinate strategic and operational cooperation to 
address these in a more coherent way; 
                                                 
1
 15074/04 CORDROGUE 77 SAN 187 ENFOPOL 178 RELEX 564 
2
 OJ 2005/C 168/01 
3
 OJ 2008/C 326/09 
4
 13407/08 CORDROGUE 69 SAN 195 ENFOPOL 164 RELEX 682 + ADD3 
5
 OJ 2010/C 115/24 
6
 8821/10 JAI 320 COSI 20 CORDROGUE 40 CRIMORG 79 JAIEX 39 
7
 15544/11 JAI 740 COSI 82 CORDROGUE 66 ENFOPOL 360 CRIMORG 184 JAIEX 111 UD 261 
8
 15358/10 COSI 69 ENFOPOL 298 CRIMORG 185 ENFOCUSTOM 94 
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- the Commission Communication “Towards a stronger European response to drugs”
9
, which 
outlines current challenges in the field of drugs, while presenting proposals to address them; 
- the Internal Security Strategy for the European Union
10
, which identifies drugs trafficking as a 
form of criminality requiring concerted European action; 
- the UN Political Declaration and Action Plan on International Cooperation towards an 
Integrated and Balanced Strategy to Counter the World Drug Problem which enumerates drug 
demand and drug supply reduction measures to be taken by the participating states
11
; 
 
REITERATIG THAT 
 
- drug policy is mainly the competence of the EU Member States; 
- the aim of the EU Drugs Strategy 2005-2012 was to add value to national strategies while 
respecting the principles of subsidiarity and proportionality set out in the Treaties; 
- that the strategy intended to allow scope for local, regional, national and transnational 
dynamics and potentialities and to make optimal use of the resources available; 
- the EU Drugs Strategy 2005-2012 was based on an integrated, multidisciplinary and balanced 
approach, addressing with equal vigour drug demand and supply reduction. 
 
OTIG THAT 
 
- even though the nature and characteristics of the illicit drug problem have changed since the 
beginning of the EU Drugs Strategy 2005-2012, the fundamental challenges within the EU 
remain the same; 
- drug use in the EU appears to be relatively stable; prevalence levels overall remain high, but 
are not rising, and in some important areas, such as cannabis use by young people, there are 
positive signs; 
- there are, however, indications of worrying developments in the synthetic drugs market and, 
more generally, in the way drug consumers now use a wider set of substances; 
 
                                                 
9
 COM (2011) 689 final 
10
 5842/10 JAI 90 
11
 http://www.unodc.org/documents/commissions/CND-Uploads/CND-52-RelatedFiles/V0984963-
English.pdf  
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- heroin continues to constitute the biggest drug problem in the EU, as heroin use accounts for 
the largest share of drug-related diseases and deaths and prevalence level remains stable at an 
estimated 1.3 million regular opioid users in the EU; however treatment data indicate that the 
characteristics of opioid problem is changing as opioid users have become older and the 
proportion of injectors has declined; 
- cannabis continues to be the most commonly used illicit drug in the EU as the most recent 
estimates of drug use in Europe from the EMCDDA show that about 12 million European 
adults, on average about 3.6% of the adult population, have used cannabis in the last month; 
- cocaine has become the second most commonly used illicit drug in the EU, although 
prevalence levels and trends differ considerably between Member States. 
 
BEARIG I MID 
 
- the outcomes of the assessment of the implementation of the EU Drugs Strategy 2005-2012 
and its Action Plans which inter alia demonstrated: 
- that the Strategy has provided added value to individual Member States and their 
strategies by offering a platform for consensus building and coordination in relation to a 
horizontal and increasingly international issue; 
- that the Strategy helped the EU and its Member States to speak with one voice at 
international fora and that it promoted a clearly recognisable and acknowledged ‘EU 
approach to tackling drug-related challenges; 
- that the Horizontal Drugs Group (HDG) has functioned as the main coordinating body at 
the EU level and has facilitated information exchange between Member States as well as 
contributed to the formation of common positions on the external dimension of the EU 
drugs policy; however the coordinating role of the HDG in the area of supply reduction 
is becoming more complicated, as law enforcement activities in drugs policy have also 
become a priority on the EU internal security agenda; 
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- that the strategy had some success in the field of demand reduction, especially in 
promoting an evidenced-based approach; however persistent challenges remain, 
especially in relation to different levels of implementation of harm reduction measures 
and drug treatment in the Member States, difficulties of coordination and 
implementation at the national level, and the continued funding of demand reduction 
programmes in an economic downturn; 
- that with respect to supply reduction the objectives of the Strategy and Actions Plans are 
considered relevant to addressing the drugs challenges faced in the EU; however the 
measurability of progress in this area remains a challenge; 
- that international cooperation on drugs policy is a key area where the EU adds value to 
Member State efforts to coordinate and address drugs challenges; 
- that there are considerable achievements in the field of information, research and 
evaluation; however there is scope for a greater focus to expand and improve the 
knowledge base around supply reduction; 
- that the EMCDDA plays a key role as a facilitator, shaper and supporter of efforts in the 
area of information, research and evaluation across the EU. 
 
COSIDERIG THAT 
 
- new and potentially harmful psychoactive substances, often being marketed as legal 
alternatives to internationally controlled drugs, are emerging at unprecedented pace posing a 
risk to public health and safety; 
- the increase in poly-drug use, including the combination of illicit drugs with alcohol, and 
sometimes, medicines and unregulated new psychoactive substances, which can lead to 
multiple adverse health consequences, represents an increasing challenge; 
- drug traffickers exploit the EU internal market as well as the possibilities provided by modern 
technologies and develop innovative methods for diverting drug precursors and smuggling 
drugs into and within the EU; 
- illicit drugs remains a major criminal commodity in the EU and intelligence suggests that 
there is a trend towards increased cooperation between national criminal networks and that 
drug trafficking is an integrated part of poly-criminal activities; 
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- although there is an increasing level of interventions and programmes in the field of drug-
demand reduction in the Member States, there are still large differences between and within 
Member States when it comes to the quality, accessibility and coverage of such interventions; 
- infectious diseases related to injecting drug use such as Hepatitis C Virus (HCV) and HIV 
continue to pose serious health risks, including the potential risk of new outbreaks of HIV and 
of other blood-borne infections related to injecting drug use in certain regions within the EU 
and in neighbouring regions
12
; 
- the illicit drug problem in all its facets continues to pose serious risks to the health and safety 
of EU citizens, and to the stability, security, health and development of countries outside the 
EU, including the Candidate and Associated and Neighbourhood countries, as well as third 
countries along the trafficking routes. 
 
AGREES THAT 
 
1. the EU needs an EU drugs strategy for 2013-2020 as the political framework in the field of 
drugs, which should be adopted by the end of 2012; 
2. the new strategy should be a concise document concentrating on five thematic areas: 
coordination; demand reduction; supply reduction; international co-operation and research, 
information and evaluation; 
3. the new strategy shall contain a limited number of clearly defined strategic objectives, setting 
out the longer-term strategic development of EU drugs policy, and consolidating and building 
on existing instruments; 
4. the detailed implementation of the new strategy should be set out in two consecutive action 
plans covering each a period of four years; 
5. the present integrated, multidisciplinary and balanced approach should continue to form the 
basis of the EU approach to the drug problem in the future; drug demand and drug supply 
reduction measures shall be based on available evidence, well balanced, and implemented 
with equal vigour; 
6. in the implementation of the new strategy, appropriate resources should be allocated to 
measures in both drug demand and drug supply reduction as well as to measures of a 
horizontal nature;    
                                                 
12
 EMCDDA report on the drugs situation in Europe in 2011, doc. 17139/11 CORDROGUE 78 + ADD1 
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7. demand reduction in the new integrated strategy includes universal as well as targeted 
prevention, early intervention, treatment, care, risk and harm reduction, recovery, social 
reintegration, initiatives in prison settings and measures to ensure and improve quality and 
standards; 
8. supply reduction activities in the new strategy should remain focused on cooperation between 
law enforcement authorities, including through exchange of information and joint operations 
and investigations, and on coordination of law enforcement initiatives, including in regard to 
regional projects and control of illicit drugs entering the EU by sea and by air; 
9. the new strategy should take on board new approaches and address new challenges which 
have been identified in recent years, including those related to new or ongoing threats to the 
health and safety of EU citizens, especially:  
- poly-drug use, including the combination of illicit drugs and alcohol,  
- the rapid spread of new psychoactive substances, 
- ensuring access to and addressing the misuse of prescribed controlled medications,  
- the dynamics in the drug markets, including the use of the internet as a facilitator for 
the distribution of illicit drugs,  
- the diversion of precursors used in the illicit manufacture of drugs, 
- the quality of demand reduction services,  
- the high incidence of blood borne diseases, especially HCV, among injecting drug 
users and potential risks of outbreaks of HIV epidemics and other blood borne 
infections related to injecting drugs use; 
10. the new strategy should further promote an intelligence and evidence-based approach to the 
drug problem, recognising work under the EU policy cycle for organised and serious 
international crime as part of the wider EU internal security agenda;  
11. in formulating the new strategy appropriate consideration should be given to 
recommendations put forward by high-level scientific societies as well as the opinion of the 
civil society; 
12. the new strategy should take note of the progress made towards minimum quality standards in 
drug demand reduction and of key indicators in drug supply reduction, as well as of other 
available indicators;  
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13. the new strategy should also focus on improving the internal EU coordination, as the HDG as 
the main coordinating body should further align its activities with other EU initiatives 
touching upon drugs policy, in particular the EU policy cycle for organised and serious 
international crime and other initiatives within COSI as well as initiatives in the health area, 
and take into account the work of the EU agencies; 
14. the drugs situation should continue to be monitored in order to create a knowledge base for a 
better common understanding of the drugs problems and the development of an optimal 
response to new trends, especially concerning supply of drugs and the impact of interventions 
to reduce supply; 
15. in this regard, information, research, analysis, evaluation, and the collection and exchange of 
information by the EMCDDA through its network of national focal points and the Early 
Warning System as well as by other EU bodies should continue to be supported; 
16. projects and programmes to foster alternative development and alternative livelihoods in 
drug-producing countries should continue to be supported since illicit drug crop cultivation is 
in many countries linked to development problems such as poverty, weak rural development, 
fragile statehood and violence; 
17. with respect to international cooperation, the EU approach should continue to be 
comprehensive, focusing on cooperation with strategic partners: in particular the existing 
dialogues with international partners, including the countries in the Western Balkans, Latin 
America and the Caribbean (including the Andean Community countries), West Africa, 
Central Asia and Afghanistan, the Eastern Partnership, Russia, and the United States, should 
be further improved to ensure a greater level of knowledge of the strategies, objectives and 
relevant initiatives amongst individuals and organisations having responsibilities in the area of 
drugs policy in third countries and in the EU; 
18. to ensure continuous focus on the implementation of the strategy and of its accompanying 
action plans, and on monitoring and evaluation of outcomes, each Presidency should towards 
the end of its six-month term give an overview to the HDG of the activities carried out in 
regards to any action plan in force; 
19. at the end of the period covered by the new strategy and each action plan, an evaluation needs 
to be conducted in order to provide input and recommendations for the future development of 
EU drugs policy. 
 
 
________________________ 
